Incyte Corporation  

(Public, NASDAQ:INCY)   Watch this stock  
Find more results for INCY
-0.08 (-0.07%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 112.71 - 114.39
52 week 83.01 - 153.15
Open 113.74
Vol / Avg. 1.57M/1.94M
Mkt cap 24.05B
P/E     -
Div/yield     -
EPS -0.78
Shares 210.65M
Beta 0.92
Inst. own 93%
Oct 31, 2017
Q3 2017 Incyte Corp Earnings Call - 10:00AM EDT - Add to calendar
Oct 31, 2017
Q3 2017 Incyte Corp Earnings Release - 7:00AM EDT - Add to calendar
Sep 9, 2017
Incyte Corporation Presents at European Society for Medical Oncology Annual Congress, ESMO 2017, Sep-09-2017 05:00 PM
Aug 1, 2017
Q2 2017 Incyte Corp Earnings Call - Webcast
Aug 1, 2017
Q2 2017 Incyte Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -3.82% 9.43%
Operating margin 2.21% 13.11%
EBITD margin - 18.40%
Return on average assets -3.08% 7.88%
Return on average equity -5.03% 35.29%
Employees 980 -
CDP Score - -


1801 Augustine Cut off
WILMINGTON, DE 19803-4404
United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Officers and directors

Herve Hoppenot Chairman of the Board, President, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
David W. Gryska Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Reid M. Huber Executive Vice President, Chief Scientific Officer
Age: 45
Bio & Compensation  - Reuters
Eric H. Siegel Executive Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Paula J. Swain Executive Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Barry P. Flannelly Executive Vice President and General Manager , US
Age: 59
Bio & Compensation  - Reuters
Vijay Iyengar Executive Vice President, Global Strategy and Corporate Development`
Age: 44
Bio & Compensation  - Reuters
Wenqing Yao Ph.D. Executive Vice President, Head of Discovery Chemistry
Age: 54
Bio & Compensation  - Reuters
Steven H. Stein M.D. Vice President and Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 50
Bio & Compensation  - Reuters